Management of psychiatric symptoms in anti-NMDAR encephalitis: A case series, literature review and future directions

General Hospital Psychiatry

Volumn 36, Issue 4, 2014, Pages 388-391

  Kuppuswamy, Preetha S ^a   Takala, Christopher Robert ^a   Sola, Christopher L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antipsychotic agents; Behavioral symptoms; Benzodiazepines; ECT; Limbic encephalitis; Mood stabilizer; N methyl D aspartate receptor

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DESVENLAFAXINE; ETIRACETAM; IMMUNOGLOBULIN; LORAZEPAM; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; PREDNISONE; QUETIAPINE; RITUXIMAB; SERTRALINE; VALPROIC ACID; ZIPRASIDONE;

ABDOMINAL PAIN; ADULT; AGITATION; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ANXIETY DISORDER; APATHY; ARTICLE; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; CATATONIA; CAUCASIAN; CONFUSION; CONTROLLED STUDY; DELUSION; DEPRESSION; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EROTOMANIA; ETHNICITY; FEMALE; FEVER; HALLUCINATION; HUMAN; HYPERSALIVATION; IMPULSIVENESS; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL DISEASE; MUSCLE RIGIDITY; MUTISM; NAUSEA; NIGHT SWEAT; PARANOIA; PLASMAPHERESIS; PSYCHOSIS; SEIZURE; SEX DIFFERENCE; SLURRED SPEECH; SUICIDAL IDEATION; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; CASE REPORT; COMPLICATION; METABOLISM; MOOD DISORDERS; PSYCHOTIC DISORDERS;

ADULT; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; CATATONIA; FEMALE; HUMANS; MALE; MOOD DISORDERS; PSYCHOTIC DISORDERS;

EID: 84902796900     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2014.02.010     Document Type: Article

References (44)

1. Chapman M.R., Vause H.E. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry 2011, 168(3):245-251.
2. Dalmau J., Gleichman A.J., Hughes E.G., Rossi J.E., Peng X., Lai M., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7(12):1091-1098.
3. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10(1):63-74.
4. Peery H.E., Day G.S., Dunn S., Fritzler M.J., Prüss H., De Souza C., et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012, 11(12):863-872.
5. Titulaer M.J., McCracken L., Gabilondo I., Armangué T., Glaser C., Iizuka T., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013, 12(2):157-165.
6. Yu A.Y., Moore F.G. Paraneoplastic encephalitis presenting as postpartum psychosis. Psychosomatics 2011, 52(6):568-570. [Epub 2011 Sep 23.]. 10.1016/j.psym.2011.01.043.
7. Barry H., Hardiman O., Healy D.G., Keogan M., Moroney J., Molnar P.P., et al. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry 2011, 199(6):508-509. [Epub 2011 Oct 7]. 10.1192/bjp.bp.111.092197.
8. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32(9):1888-1902. [Epub 2007 Feb 14].
9. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37(1):4-15. 10.1038/npp.2011.181. [Epub 2011 Sep 28].
10. Matsumoto T., Matsumoto K., Kobayashi T., Kato S. Electroconvulsive therapy can improve psychotic symptoms in anti-NMDA-receptor encephalitis. Psychiatry Clin Neurosci 2012, 66(3):242-243. 10.1111/j.1440-1819.2012.02324.x.
11. Javitt D.C. Glutamate involvement in schizophrenia: focus on N-methyl-d-aspartate receptors. Primary Psychiatry 2006, 13(10):38-46.
12. Kung D.H., Qiu C., Kass J.S. Psychiatric manifestations of anti-NMDA receptor encephalitis in a man without tumor. Psychosomatics 2011, 52(1):82-85. 10.1016/j.psym.2010.11.010.
13. Maggina P., Mavrikou M., Karagianni S., Skevaki C.L., Triantafyllidou A., Voudris C., et al. Anti-N-methyl-d-aspartate receptor encephalitis presenting with acute psychosis in a preteenage girl: a case report. J Med Case Rep 2012, 6(1):224. 10.1186/1752-1947-6-224.
14. Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis in psychiatry. Current Psychiatry Reviews 7(3)2011:189-193(5).
15. McCarthy A., Dineen J., McKenna P., Keogan M., Sheehan J., Lynch T., et al. Anti-NMDA receptor encephalitis with associated catatonia during pregnancy. J Neurol 2012, 259(12):2632-2635.
16. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17(8):2921-2927.
17. Kjaerby C, Broberg BV, Kristiansen U, Dalby NO. Impaired GABAergic inhibition in the prefrontal cortex of early postnatal phencyclidine (PCP)-treated rats. Cereb Cortex. 2013.
18. Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand 2013;(441 Suppl):1-47. http://dx.doi.org/10.1111/acps.12038.
19. Braakman H.M., Moers-Hornikx V.M., Arts B.M., et al. Pearls and oysters: electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology 2010, 75:e44-e46.
20. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl). 2004;174(1):143-50. [Epub 2003 Dec 9].
21. Watkins C.J., Pei Q., Newberry N.R. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Brain Res Mol Brain Res 1998, 61(1-2):108-113.
22. Ishihara K., Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol 1999, 80(3):185-189.
23. Damgaard T., Larsen D.B., Hansen S.L., Grayson B., Neill J.C., Plath N. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav Brain Res 2010, 207(1):144-150. [Epub 2003 Mar 26]. 10.1016/j.bbr.2009.09.048.
24. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl). 2004;174(1):143-50. [Epub 2003 Dec 9].
25. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994, 17:31-108.
26. Kim S.H., Price M.T., Olney J.W., Farber N.B. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol Psychiatry 1999, 4(4):344-352.
27. Farber N.B., Foster J., Duhan N.L., Olney J.W. Alpha 2 adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology 1995, 12(4):347-349.
28. Farber N.B., Hanslick J., Kirby C., McWilliams L., Olney J.W. Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 1998, 18(1):57-62.
29. Farber N.B., Jiang X.P., Heinkel C., Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry 2002, 7(7):726-733.
30. Farber N.B., Foster J., Duhan N.L., Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr Res 1996, 21(1):33-37.
31. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002, 7(1):32-43.
32. Sansing L.H., Tuzun E., Ko M.W., Baccon J., Lynch D.R., Dalmau J. A patient with the encephalitis associated with the NMDA receptor antibodies. Nat Clin Pract Neurol 2007, 3:291-296.
33. Farber N.B. Ann N Y. NMDA receptor hypofunction model of psychosis. Acad Sci 2003, 1003:119-130.
34. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998, 812(1-2):65-75.
35. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33(6):523-533.
36. Jentsch D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999 Mar, 20(3):201-225.
37. Coyle J.T., Tsai G., Goff D., Ann N.Y. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Acad Sci 2003, 1003:318-327.
38. Takahat R., Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 2003, 28(6):1117-1124. [Epub 2003 Mar 26].
39. Tsai G.E., Lin P.Y. Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010, 16(5):522-537.
40. Thomas C., Carroll B.T., Maley R.T., Jayanti K., Koduri A. Memantine and catatonic schizophrenia. Am J Psychiatry 2005, 162(3):626.
41. de Lucena D., Fernandes B.S., Berk M., Dodd S., Medeiros D.W., Pedrini M., Kunz M., Gomes F.A., Giglio L.F., Lobato M.I., Belmonte-de-Abreu P.S., Gama C.S. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009, 70(10):1416-1423.
42. Dhossche D., Fink M., Shorter E., Wachtel L. Anti-NMDA receptor encephalitis versus pediatric catatonia. Am J Psychiatry 2011, 168(7):749-750.
43. Lee A., Glick D., Dinwiddie S. Electroconvulsive therapy in a pediatric patient with malignant catatonia and paraneoplastic limbic encephalitis. J ECT 2006, 22:267-270.
44. Mann A., Machado M., Liu N., Mazin A., Silver K., Afzal K. J Neuropsychiatry Clin Neurosci 2012, 24(2):247-254.